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Abstract
Chronic inflammation results when the immune system responds to trauma, injury or infec-
tion and the response is not resolved. It can lead to tissue damage and dysfunction and in
some cases predispose to cancer. Some viruses (including Epstein-Barr virus (EBV)) can
induce inflammation, which may persist even after the infection has been controlled or
cleared. The damage caused by inflammation, can itself act to perpetuate the inflammatory
response. The latent membrane protein 1 (LMP1) of EBV is a pro-inflammatory factor and in
the skin of transgenic mice causes a phenotype of hyperplasia with chronic inflammation of
increasing severity, which can progress to pre-malignant and malignant lesions. LMP1 sig-
nalling leads to persistent deregulated expression of multiple proteins throughout the mouse
life span, including TGFα S100A9 and chitinase-like proteins. Additionally, as the inflamma-
tion increases, numerous chemokines and cytokines are produced which promulgate the
inflammation. Deposition of IgM, IgG, IgA and IgE and complement activation form part of
this process and through genetic deletion of CD40, we show that this contributes to the
more tissue-destructive aspects of the phenotype. Treatment of the mice with N-acetylcys-
teine (NAC), an antioxidant which feeds into the body’s natural redox regulatory system
through glutathione synthesis, resulted in a significantly reduced leukocyte infiltrate in the
inflamed tissue, amelioration of the pathological features and delay in the inflammatory sig-
nature measured by in vivo imaging. Reducing the degree of inflammation achieved through
NAC treatment, had the knock on effect of reducing leukocyte recruitment to the inflamed
site, thereby slowing the progression of the pathology. These data support the idea that
NAC could be considered as a treatment to alleviate chronic inflammatory pathologies,
including post-viral disease. Additionally, the model described can be used to effectively
monitor and accurately measure therapies for chronic inflammation.
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Introduction
Human disease conditions displaying chronic inflammation frequently exhibit tissue degenera-
tion, functional impairment and even permanent metabolic changes as a consequence [1].
Additionally, a link between chronic inflammation and increased cancer risk has been well doc-
umented [2, 3]. Activation of inflammatory responses involve the recruitment of leukocytes to
a site, often mediated through factors released by mast cell degranulation (such as histamine)
and by activation of macrophages which release proinflammatory cytokines (including tumour
necrosis factor (TNF)-α). This process escalates with the sequential release of further inflamma-
tory mediators (chemokines, cytokines and certain lipids) and the recruitment and activation of
further inflammatory cells, which in turn release proinflammatory factors. Under normal cir-
cumstances, acute inflammation is self-limiting and though less well understood, the response
abates after a few days when the infection or injury resolves. Persistent activation of inflamma-
tion or a failure to resolve the response, resulting in chronic inflammation, can lead to dysfunc-
tion, autoimmune disease and increased cancer risk.
During inflammation, phagocytes (including neutrophils, monocytes, macrophages and
mast cells) produce oxidising enzymes (NADPH oxidase, inducible nitric oxide synthase
(iNOS), xanthine oxidase and myeloperoxidase) leading to the generation of high levels of
reactive oxygen and nitrogen species (ROS and RNS), which, in a feed forward loop, can pro-
mote further inflammation [4–7]. ROS and RNS act as signalling molecules at low concentra-
tion, but at the high concentrations released in a respiratory burst under inflammatory
conditions, ROS and RNS can damage a wide range of biomolecules, including DNA, proteins
and lipids [8]. Immune cells direct this action to eradicating infectious agents and infected
cells, but under chronic inflammatory conditions, high level ROS and RNS can contribute to
tissue damage [3].
There is wide interest in the potential of antioxidants as therapeutic agents to combat
chronic inflammation and considerable controversy over the benefits of antioxidants verses
oxidants in the prevention and treatment of cancer. N-acetylcysteine (NAC) is an antioxidant
which is freely available over the counter. NAC is used clinically to treat a wide variety of medi-
cal issues and conditions [9], such as paracetamol overdose, acute respiratory distress syn-
drome, chemotherapy and heavy metal-induced toxicity; it’s also used as a mucolytic agent
[10] and to ameliorate certain psychiatric disorders [11, 12]. Furthermore, NAC has been
reported to have multiple other beneficial properties, such as enhancing bone regeneration,
reducing tinnitus, reducing post surgical complications [13] and protective effects during
mutagenic irradiation [14].
NAC is the acetylated precursor of cysteine, a semi-essential amino acid with a thiol side
chain. Cysteine, can cross cell membranes (including the blood brain barrier) and is the rate-
limiting molecule in the synthesis of the tripeptide glutathione (GSH; derived from glutamic
acid, cysteine and glycine). GSH is a major endogenous antioxidant in the body, the thiol
group serving as an electron donor in reducing reactions, during which GSH is oxidized to
form glutathione disulphide (GSSG). Indeed GSH maintains vitamins C and E in their reduced
(active) form. GSH has several essential functions in the body, as well as antioxidant activity
(including scavenging ROS and RNS), it is involved in iron metabolism, it is used in biosynthe-
sis, amino acid transport and enzyme activation. While NAC itself is a reducing agent, its
rapid deacetylation in vivo, suggests that the effects of NAC in vivo largely reflect its action in
maintaining GSH levels [9]. Consequently NAC (through GSH) can effect many biological
processes, including mutagenesis and carcinogenesis, cell cycle, apoptosis, signal transduction
and gene expression, immune modulation, the cytoskeleton, trafficking and neurotransmis-
sion, amongst others [9].
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Clinical and animal studies have shown that NAC can reduce the acute inflammatory
response to lung injury and sepsis and to myocardial injury, reducing tissue damage and
improving impaired function [15–21]. However, in a long term study (24 weeks) NAC treat-
ment of cystic fibrosis subjects revealed improved lung function in the treatment group, but
no alterations in sputum inflammatory markers [22].
Inflammation following infection is a common complication, particularly after certain viral
infections and occasionally bacterial. Epstein-Barr virus (EBV) is a notable contributor to
inflammatory post-viral disease, including chronic fatigue syndrome following infectious
mononucleosis [23], viral arthritis [24] and the life threatening condition of acute dissemi-
nated encephalomyelitis [25]. Indeed EBV is known to be a risk factor for the autoimmune dis-
orders multiple sclerosis (MS) [26] and Systemic Lupus Erythematosus (SLE) [27], amongst
others. In many cases there may be little evidence of active viral disease and the inflammation
may reflect a footprint left by the response to the virus.
In this study, the impact of long term NAC treatment on chronic inflammation has been
analysed, using a transgenic mouse model of chronic inflammation-associated carcinogenesis,
induced by the latent membrane protein 1 (LMP1) of EBV [28]. LMP1-expressing cancers
associated with EBV, including nasopharyngeal carcinoma (NPC) and the B-cell malignancy
Hodgkin’s disease (HD), have an extensive leukocyte infiltrate in the tumours, to the degree
that in the latter, the malignant cells make up only 1–2% of the tumour mass [29]. LMP1 dis-
plays multiple oncogenic properties and also acts as a pro-inflammatory factor [30]. Trans-
genic LMP1 expression leads to activation of several signalling pathways, including epidermal
growth factor receptor (EGFR) pathways, constitutive activation of the JNK and NF-κB path-
ways and vascular endothelial growth factor (VEGF) upregulation [28, 31]. In the L2LMP1
mouse model, the transgene is expressed in epithelia; in the skin of the ears to the highest level
[28]. As a consequence, phenotypic progression in this relatively hairless tissue can be readily
monitored and we have categorized it into 5 pre-neoplastic stages. The inflammatory pheno-
type associated with these pathological stages has been previously described in detail [30]. At
weaning (3 weeks old) the tissue shows increased vascularization (termed stage 1). This pro-
gresses within the next month to evident tissue thickening through hyperplasia and with the
onset of an inflammatory infiltrate (stage 2). Over the next months the pathology worsens,
showing increasingly severe hyperplasia, parakeratosis, ulcerative dermatitis, fibrovascular
hyperplasia of the underlying dermis and necrosis (stages 3 through to 5). By 6 months of age,
keratoacanthomas, papillomas and occasional carcinomas begin to form, both on the ears and
other areas of skin [28]. The inflammatory infiltrate is mixed in this chronically inflamed tis-
sue, involving activated CD8+ T cells, CD4+ T cells (including regulatory T cells), mast cells
and neutrophils and a significant IgG deposition occurs in the dermis [30]. Multiple pro-
inflammatory cytokines and chemokines (including IL-1β, CCL3, CCL5, CXCL1, CXCL2 and
CXCL5) become upregulated as the pathology progresses, along with several other leukocyte
attractants and trafficking factors (including CCL19, CCL20, CCL27, CXCL10, CXCL13,
XCL1 and L-selectin). T-helper cell specific cytokines also become upregulted; at early pheno-
typic stages a mixture of Th1 (IFNγ, IL-2 and CXCL16), Th2 (IL10 and IL13) and Th17 (IL17)
responses co-exist, while at later stages (stage 4/5) a more destructive Th1 response dominates,
consistent with the necrotic phenotype [30].
The importance of inflammatory pathways in EBV associated carcinogenesis has recently
been highlighted in an extensive exome sequencing study of NPC samples, both in terms of
somatic carcinogenic mutations and germ-line susceptibility loci [32, 33]. Additionally, the
noted association of EBV infection with multiple post viral inflammatory and auto-immune
conditions renders this a particularly focus for therapeutic approaches. As such, agents that act
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to limit chronic inflammation may be of benefit both to non-malignant chronic inflammatory
disorders as well as in the treatment of some inflammation-associated malignancies.
Here, we report that treatment of L2LMP1 mice with NAC depresses and delays the chronic
inflammatory phenotype and we have quantified this by in vivo imaging.
Materials and methods
Mice
The L2LMP1 transgenic mouse line 117 (LMP1 of CAO EBV strain, aka LMP1CAO, linked to
L2 expression control sequences), in the FVB mouse strain was used in these studies, with
transgene negative siblings used as controls (NSC), as previously described [28]. CD40 null
mice (in a C57Bl/6 background) [34] were crossbred with L2LMP1 mice, back-crossed 4 times
to the FVB strain and then inter-crossed to establish LMP1/CD40KO (93.75% FVB). Pheno-
type scoring was conducted on a weekly basis and compared to CD40 wild type mice of the
same strain mix background. Ear pinnae thickness was measured with calipers. Mice were
monitored at least twice weekly to assess health and well-being. Mice were removed from
study using an approved schedule 1 method. Tissue samples were frozen in liquid N2 and
stored at -70˚C for sample extraction. For NAC treatment, NAC was supplied in the drinking
water at 10g/dm3 and the water was replaced every 3 days.
Ethics statement
All animal work was conducted, all protocols approved and this study was approved, under
UK Home Office license and according to institutional, national (Animal Welfare and Ethical
Review Body, AWERB) and international guidelines: the UK’s Animals (Scientific Procedures)
Act 1986 as amended by Animals (Scientific Procedures) Act 1986 Amendment Regulations
2012. This law is derived from the EU Directive on the Protection of Animals used for Scien-
tific Purposes (Directive 86/609/EEC as updated by Directive 2010/63/EU).
Isolation of leukocytes from ear tissue
Cells were isolated from ear tissue, essentially as described [30]. Briefly, the collected tissue was
finely minced in 2ml PBS/ear, then 10mg/ml collagenase II, 10mg/ml collagenase IV, 0.5mg/
ml DNaseI, CaCl2 to 3mM, were added and incubated at 37˚C for 30 mins (shaking). Then dis-
pase-II was added to 5mg/ml and incubated 15 mins, 37˚C (shaking). To the cell samples (per
1 or pair of ears), two volumes of PBS + 10%FCS was added and then passed through a 40μm
filter to remove clumps (with a follow through filter wash of 5ml PBS). Collected cells were
washed 2x with 10ml PBS (centrifugation 194xg, 10 mins). Then, either the whole sample or
106 cells per sample was retained for flow cytometry.
Leukocyte transfer in vivo
Isolated and washed cells from the ears of 2 mice (approximately 107 cells after removal of an
aliquot for flow cytometry) were re-centrifuged and resuspended in 10ml complete medium
(RPMI, 20% FCS, 1%glutamine, 1%penicillin/streptomycin (Sigma)) and incubated 37˚C
overnight. Suspension cells were collected, counted, washed in PBS and resuspended in 300μl
complete medium and stained with cell proliferation dye (CPD eBioscience) at 80μM, for 5
mins at RT. Cells were washed 2x with 5ml PBS and resuspended at 106cells/150μl PBS and
kept on ice for IV injection into the tail vein.
NAC ameliorates chronic inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0189167 December 11, 2017 4 / 20
In vivo imaging system (IVIS)
For imaging CPD stained cells in vivo, mice were inhalation anaesthetised with 4% isofluorane
and 0.5L/min oxygen. Epi-fluorescence imaging was conducted using λ 640nm excitation and
680nm emission, first at low magnification to view the passage of cells from the tail and subse-
quently at higher magnification to examine ears. Images were acquired and analysed using
LivingImage v4.3.1 (PerkinElmer), binning setting of 4, exposure time 1 second. Fluorescent
images were captured from 1 to 48 hours post injection (hpi) and regions of interest (ROI)
were drawn around the ears to obtain the average radiance efficiency (ARE) in ([photons/s/
cm2/sr]/[μW/cm2]).
For inflammation imaging in vivo, mice were injected IV with 0.3 to 2nmol ProSense 680
(p680, PerkinElmer) in 200μl PBS. Mice were anaesthetised at time points, from 1 to 48 hpi
and fluorescent images captured using λ 675nm excitation and 720nm emission. Images were
analysed and radiance from ROI quantified.
Western blotting
Proteins were extracted in RIPA buffer and were separated (30–100μg per track) by SDS-
PAGE (7.5%, 10% or 15%); blotting and washing were performed as previously described [30].
The blots were incubated in 5% non-fat milk PBS 0.1% (v/v) Tween 20 with the appropriate
antisera. Antibodies (with dilutions) used were directed to: LMP1 (IG6) 1:100, TGFα (Santa-
cruz) 1:1000, Chil3/4(YM1/2) (R&D systems) 1:1000, SOD1 (Santacruz) 1:200, Erk1/2 (Cell
Signaling) 1:1000, phosphor-Erk1/2 (Cell Signaling) 1:1000, Stat3 (Cell Signaling) 1:1000,
S100A9 (R&D Systems) 1:1000, EGFR (Cell Signaling) 1:1000, IκBα (Cell Signaling) 1:1000,
phosphoIκBα (Cell Signaling) 1:1000, GAPDH (Santacruz) 1:1000, actin (Santacruz) 1:1000,
IgE (Abcam) 1:1000, followed by the appropriate 1:4000 goat anti-mouse, anti-rabbit, anti-rat,
or donkey anti-goat IgG HRP-conjugates (Santacruz). Mouse IgM, IgA and IgG were detected
directly using antibody HRP-conjugates (Santacruz or Southern Biotech.) 1:4000. Detection
was performed by enhanced chemiluminescence (liteAblot kit, Euroclone) and bands on blot
images quantified using imageJ.
Flow cytometry
To cells in 300μl to 700μl PBS, TruStain (BioLegend) was added at 1μg/100μl for 10 mins on
ice. Cell aliquots (105 to 106) were made up to 200μl with PBS and incubated with fluorescent
marker conjugated antibodies directed against: CD45-FITC or CD45-APC (BioLegend) at
37˚C, 25 mins. For ROS detection, 2μl of DCFH-DA was added to each sample at the same
time as anti-CD45 and samples were incubated at 37˚C, 15 mins. Samples were washed with
1ml PBS (centrifugation 400g, 5 mins) and either washed again and resuspended in 500μl PBS,
1% FCS for FACS or fixed in 100μl 2% buffered paraformaldehyde, 15 mins dark. Fixed cells
were centrifuged and resuspended in 100μl PBS and stored in the dark, overnight, 4˚C. Before
analysis, fixed cells were pelleted and resuspended in 500μl PBS, 1% FCS. Samples were sorted
using FACSCalibur or FACSAria (BD Biosciences) and data acquired using FlowJo and ana-
lysed using Kaluza 1.2 (Beckman-Coulter). Statistical analyses were carried out using Graph-
Pad Prism 5, using paired T-tests.
Results
Immunoglobulins of all isotype groups are detected in the inflamed tissue
LMP1 acts as a proliferative and pro-inflammatory factor in the skin of L2LMP1 transgenic
mice, particularly evident where the transgene expression is highest, in the ear skin. The
NAC ameliorates chronic inflammation
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phenotype has been categorised by visible parameters into stage categories (described above)
[28], supported by ear thickness measurements. At stage 2, prior to the appearance of haemor-
rhagic or necrotic foci, the ear pinnae were significantly (p<0.0001) thickened compared to
transgene negative sibling controls (NSC), by approximately 3 fold, from a mean of 0.21mm
(SD +/-0.05) in NSC mice of all ages to a mean of 0.6mm (SD+/- 0.19) (p = 0.001). The pinna
thickness increases further with progressive stage. The advancing phenotype can also be evi-
denced by examination of immunoglobulin (Ig) deposition in the dermis (previously shown
by western blotting and immunohistochemistry) [30]. Tissues categorised from stage 3 to
stage 5 show consistently more IgG deposition in the tissues compared to controls (Fig 1).
We have previously observed that CD40 is strongly upregulated in the transgenic inflamed
skin [30] and it is also expressed in NPC tumour samples [35]. CD40 has broad functions in
immune and inflammatory responses, but in particular, it is a potent activator of B-cells and is
essential for immunoglobulin class switching to IgG and IgE, memory B-cell development and
germinal centre formation [34]. Additionally it has been observed that LMP1 can substitute
for some functions of CD40 [36]. To explore the role of CD40 and B-cell activation in the
transgenic LMP1 induced inflammation, L2LMP1 mice were cross-bred into a CD40 null
background. There was no observable impact upon the early hyperplastic and inflamed stages
(stages 2 and 3) of the LMP1-induced phenotype in the CD40 null background, however the
mice showed a significant reduction in the ulcerative and necrotic lesions evident in the highly
inflamed tissues at stage 4, with none advancing to stage 5 (Fig 2A). In a CD40-wild type back-
ground, IgG, IgM, IgA, IgE and the cleaved complement protein C3c were all induced in the
L2LMP1 inflamed skin compared to NSC (Fig 2B). Western blotting confirmed the absence of
IgG and IgE, as well as complement C3c, in the CD40 null skin tissue, however, the LMP1
transgenic samples nevertheless showed an increase in IgM and IgA levels compared to NSC,
in both a CD40-wild type and CD40 null background. These data show that CD40 action
(including IgG and IgE production and complement system activation), contributes to the tis-
sue degenerative aspect of the inflammatory phenotype seen in older mice, without apparent
contribution to the early, proliferative features of the phenotype.
NAC treatment delays the progression of the inflammatory phenotype
In order to explore if the feed-forward loop between oxidative stress and chronic inflammation
could be disrupted, the effect of long-term NAC treatment was examined. Under acidic condi-
tions (such as gastric fluid), NAC can cross cell membranes, but once in the systemic circula-
tion, under neutral conditions, negatively charged NAC cannot cross intact, unimpaired
membranes, however, with deacetylation, cysteine can [9]. The half-life of NAC in the body,
administered by intravenous injection, is approximately 5.6 hours, with 30% cleared by renal
excretion [9]. Therefore, in order to provide a continuous NAC regimen, transgenic and NSC
mice were treated with NAC in the water supply, either from birth or starting at approximately
1 month of age (30–40 days old). Supplying NAC-water postpartum resulted in a reduced pup
weight at weaning for transgenic, but not wild type mice, while treatment from 1 month of age
caused no weight loss. Subsequently, all treatments were initiated in mice at 1 month old (at
which point transgenic mice show a stage 1 phenotype) and treatment was generally continued
throughout life. The phenotypic progression was monitored in NAC treated and untreated
L2LMP1 transgenic mice. Mice treated with NAC showed significantly slower phenotypic pro-
gression (p<0.0001 from 7 weeks of age onwards), with a prolonged period transiting stages 1
to 3 (Fig 3). In addition, some NAC treated mice showed a temporary phenotype reversal,
reverting from stage 2 to a stage 1 or 1/2 intermediary state, before slowly progressing on again
to stage 2 some weeks later (S1 Fig). However, given time, the phenotype could reach stages 4
NAC ameliorates chronic inflammation
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and 5 in some NAC treated mice. It was observed that the earlier the age the treatment was
started, the more pronounced the retardation of phenotype progression (S1 Fig).
Fig 1. IgG deposition in the transgenic ear tissue increases with phenotypic stage and age. Protein (50μg/
track) was extracted from L2LMP1 transgenic ears (stages 1 to 5, upper blot as indicated) and control (NSC lower
blot) of mice of increasing age and western blotted (age in days, as indicated above or below (respectively)). The
blots were probed with antibodies to actin (42kD) and GAPDH (37kD), using anti-mouse IgG as secondary, also
detecting tissue immunoglobulin-G: IgH and IgL, as indicated. Protein size markers in kD are indicated to the left of
each panel. Below: the normalised values (IgH/actin) are shown graphically for transgenic (L2LMP1) and NSC
samples, plotted against age.
https://doi.org/10.1371/journal.pone.0189167.g001
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Fig 2. IgG, IgM, IgA, IgE and complement C3c levels are increased in the transgenic tissue. (A) The
phenotypic stage was monitored in a cohort of LMP1 transgenic mice in a wild type background (LMP1CD40WT:
n = 17) compared to LMP1 transgenic mice in a CD40 null background (LMP1CD40KO: n = 15) and plotted over
time; error bars show SEM. (B) Ear tissue protein samples from mice of the following genotypes: L2LMP1
transgene (LMP1tg) positive (+) or negative (-), in either a CD40 null background (ko), heterozygous (het) or wild
type for CD40 (wt) were western blotted. Age in days and phenotypic stage are indicated. The blots were probed
with antibodies to mouse IgG, IgM, IgA, IgE and complement C3 and re-probed with antibody to GAPDH (37kD).
Protein size markers in kD are indicated to the left of each panel. Note: IgG, IgE and C3c are not produced in CD40
null mice, however, IgM and IgA are induced in the LMP1 transgenic tissues.
https://doi.org/10.1371/journal.pone.0189167.g002
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Fig 3. NAC treatment delays phenotypic progression. A to G photographs of ear skin phenotype: A: The phenotype of a
transgenic mouse (right) at 42 days old, referred to as stage 1 (St1), compared to NSC (left). (B-G): The phenotypic effect of
systemic treatment of transgenic mice with NAC (right) from 38 days old, compared to untreated (left: UT) at progressive ages
and phenotypic stages. Age and stage details: B: 42 days old: left: untreated stage 1, right: 4 days NAC. C: 60 days old: left:
untreated stage 2, right: 22 days NAC. D: 84 days old: left: untreated stage 3, right: 46 days NAC. E: 100 days old: left: untreated
stage 3, right: 56 days NAC. F: 140 days old: left: untreated stage 4, right: 96 days NAC. G: 160 days old: left: untreated stage 5,
right: 116 days NAC treatment. (H) The mean age of progression to the next phenotypic stage is shown graphically for untreated
transgenic mice (n = 57, error bars show SD). (I) The average phenotypic stage with age is plotted for a cohort of transgenic mice
treated with NAC (total n = 34, with at least n = 7 for each time point) compared to untreated (total n = 188, with at least n = 10 for
each time point). Stage progression is significantly different between the two groups (P<0.0001) from 7 weeks of age onwards.
Error bars show SE. Note: drops in the curve for untreated mice do not reflect phenotype reversal but are due to removal of mice
from study.
https://doi.org/10.1371/journal.pone.0189167.g003
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In vivo quantification of the inflammatory phenotype
In order to develop a quantitative, objective measure of the inflammatory phenotype, the util-
ity of in vivo imaging using a protease activatable fluorescent agent (p680) was assessed.
Optically silent in its unactivated state, p680 becomes highly fluorescent when cleaved by lyso-
somal proteases (primarily cathepsin B, L, S and plasmin), which are frequently induced dur-
ing inflammation [37, 38]. Utilising p680 with IVIS in L2LMP1 transgenic and NSC mice was
optimised (S1 File), and subsequently, using between 0.66 and 1nmole p680/mouse was
selected, with the in vivo fluorescent signal from the ears peaking between 24 and 36 hpi.
To determine if p680 with IVIS can be used to monitor the progressive phenotype and its
retardation with NAC treatment in the L2LMP1 mice, transgenic and NSC mice at increasing
ages and phenotypic stage were imaged. Mice in approximate age groups of 57, 80, 100 and
130 days old were imaged, the transgenic, untreated mice displaying a phenotype ranging
from stage 1 to advanced stage 4 in these groups (Figures A to D and Table A in S2 File). Mice
were imaged at intervals between 3 and 36 hpi, taking the radiant efficiency of the region of
interest (ROI) (Figure E in S2 File).
The radiant efficiency measured from NSC mice showed little variation with age, averaging
3.1x108 at 24 hpi and 3.3x108 at 30hpi. L2LMP1 transgenic mice all showed significantly higher
readings at all ages and stages, at 24 and 30 hpi averaging 1.5x109 and 1.4x109 (respectively),
an order of magnitude higher than NSC (p<0.0001) (Fig 4 and Figures F and G in S2 File).
The radiant efficiency from transgenic mice varied with age and stage, showing a 2 to 3 fold
increase in mice aged 100 days old (stage 3) compared to 57 days old (stage 1). In older mice
(130 days), at phenotype stages 4 and 5, the radiant efficiency decreased to levels similar to the
young transgenic mice at stage 1. Although the phenotype becomes visibly more severe at
stages 4 and 5, the overall reduction in fluorescent signal (compared to stage 3 phenotype)
could be explained by the degeneration of the tissue, the ears become smaller, with the necrotic
regions obscuring the fluorescent signal coming from live tissue underneath (see Fig 3).
Treatment of the L2LMP1 transgenic mice with NAC resulted in a significantly reduced
fluorescent signal in mice up to 100 days old (P = 0.03), consistent with a retardation of the
observed phenotype (Fig 2). However, by 130 days of age, the signal from untreated mice
declined (with increasing necrosis), while the signal from NAC treated mice (largely free of
necrosis at this point) showed a slower decline and the difference is significant (P = 0.0003).
The data reveal that the degree of inflammation (as measured by reagent p680) increases more
slowly in transgenic mice treated with NAC, reaching a lower peak before the onset of necrosis,
compared to untreated mice. This is consistent with the phenotypic observations and provides
a quantitative measure of the effect of treatment.
NAC reduces the leukocyte load in the inflamed tissue
The leukocyte infiltrate in the inflamed tissue has been characterised previously [30]. Treat-
ment of the L2LMP1 mice with NAC resulted in a visible and quantifiable delay in the progres-
sive inflammatory phenotype. In order to assess both the impact on leukocyte load and levels of
intracellular reactive oxygen species, samples were examined by flow cytometry. Cells were iso-
lated from ear tissue from transgenic and NSC mice, either treated with NAC or untreated, at
105 days old. Dead cells were excluded by 7AAD staining and live cells were stained for CD45
(a pan leukocyte marker) and intracellular 2’,7’-dichlorofluorescein-diacetate (DCFH-DA), a
cell permeable agent which reacts with H2O2 (and other ROS) to fluoresce. The inflamed trans-
genic tissues carry a high leukocyte load compared to NSC and a substantial proportion of these
cells have high intracellular ROS (Fig 5). On average, 85.6% of the isolated cells from transgenic
ear samples were positive for CD45, showing a discrete leukocyte population and a distinct sub-
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population of leukocytes (average 20% of the total leukocytes) also staining for intracellular
ROS (DCFH-DA), possibly undergoing a respiratory burst. By contrast, significantly fewer cells
Fig 4. NAC treatment reduces the quantifiable levels of chronic inflammation in the L2LMP1 transgenic
mice. Top: typical epifluorescent image taken 24 hours after IV injection of p680 into a transgenic L2LMP1
mouse at phenotypic stage 5 (St5) and negative sibling control (NSC); colour scale shows radiant efficiency
range displayed ((photons/sec/cm2/sr)/(μW/cm2)). Below: graphs depicting the mean (with SD error bars)
radiant efficiency (Y axis) observed in mice in increasing age groups (X axis) imaged at 24 and 30 hours (as
indicated) post injection of 1nmol/mouse p680. Four groups were examined, transgenic (Tg) and NSC mice,
either untreated or treated with NAC-water. N = 2 to N = 8 for each age and group (as detailed in Table A in S2
File).
https://doi.org/10.1371/journal.pone.0189167.g004
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were CD45+ in NSC mouse samples (both treated with NAC or untreated). In addition, NSC
samples did not show a discrete proportion of cells staining for intracellular ROS, with quadrant
values significantly lower than transgenic samples (S2 Fig). Treatment of the transgenic mice
with NAC resulted in a dramatic shift in the flow data pattern; isolated transgenic cells showed
some staining with CD45, but a discrete leukocyte population is not evident. Similarly, low
DCFH-DA staining is apparent in transgenic NAC treated samples (more so than NSC sam-
ples), but a distinct population is not evident (Fig 5). Therefore, as there is no discrete popula-
tion to delineate, quadrant values were analysed. CD45+ quadrant values are significantly
reduced in the NAC treated transgenic samples compared to untreated (P<0.0001) (Fig 5). The
quadrant statistics for CD45+/DCFH-DA+ does not show a significant difference in the trans-
genic samples between NAC treatment and untreated, either in cell number or fluorescent
intensity, however, absence of the discrete ROS positive leukocyte population is clearly evident
from the FACS plots.
Fig 5. NAC treatment reduces the number of leukocytes in the inflamed tissue and their oxidative
status. Cell suspensions were generated from ear tissue from mice aged approximately 105 days old.
Samples were taken from L2LMP1 transgenic mice (Tg) treated with NAC (n = 6) or untreated (U: n = 7) and
NSC treated with NAC (n = 3) or untreated (n = 3) (as indicated) and analysed by flow cytometry. Live cells
were gated (staining negative for 7AAD) and the proportion of leukocytes (CD45+) assayed and examined for
evidence of intracellular ROS through DCFH-DA. Top panels show representative dot plots obtained for each
category. The percentage of CD45+ cells, as quantified using the quadrant values (top right and top left
quadrants combined) is graphed below. The difference between Tg U and Tg NAC and the difference
between Tg U and NSC U is statistically significant (P<0.0001).
https://doi.org/10.1371/journal.pone.0189167.g005
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These data are consistent with the phenotypic observations and IVIS quantification of
inflammation, showing that NAC treatment results in a significant reduction in the leukocyte
load in the ear tissue. Furthermore, a substantial proportion of the infiltrating leukocytes in
untreated transgenic mouse samples was positive for intracellular ROS and this population
was reduced with NAC treatment.
NAC acts to inhibit leukocyte recruitment to the inflamed tissue
The expression levels of numerous proteins are affected in the epithelium of the L2LMP1
transgenic mice compared to NSC and in some cases the levels are dynamic, changing as the
phenotype progresses [39]. TGFα, S100A9 and Stat3 are amongst several proteins consistently
induced by LMP1 in the tissue throughout the mouse life and this is not affected by NAC treat-
ment (Fig 6). Similarly, IκBα shows increased phosphorylation (reflecting the activation of
NF-κB [31]), and NAC does not affect this. Sod1, Chil3 and Chil4 (aka Chi3l3/YM1 and
Chi3l4/YM2), Erk1 and 2 and EGFR (amongst others) show a dynamic expression pattern (Fig
6 and S3 Fig). Sod1, initially induced in immature transgenic samples shows lower levels com-
pared to controls in older mice. EGFR responds to the constitutive stimulation through ligands
such as TGFα, and becomes down-regulated in the transgenic inflamed tissue [31, 40]. A simi-
lar flip in Erk1 and Erk2 activation (detected by phosphorylation) is observed, over-activated
in young transgenic mice, becoming down regulated in older, more advanced phenotypic
stages. The inflammation-associated proteins Chil3 and Chil4, highly induced in the trans-
genic tissues [41], show a flip in relative abundance as the mice age. Prolonged NAC treatment
(from the age of 30 days) shows no enduring impact on the expression levels of these key deter-
minants of proliferation and inflammation (Fig 6).
It seems likely that in acting through antioxidant pathways, NAC is damping the feed for-
ward loop between oxidative stress and inflammation. Numerous inflammatory chemokines
and cytokines are upregulated in the inflamed tissue in a complex milieu, that amplifies as the
phenotype progresses [30]. In order to explore the effect of NAC treatment upon leukocyte
recruitment to the inflamed site, activated leukocytes [42], isolated from the ears of stage 5
L2LMP1 mice were surface stained with fluorescent dye and injected into NAC treated and
untreated recipient L2LMP1 mice at approximately 100 days old (Table 1). At this age, the
NAC treated mice showed a stage 2 phenotype, while untreated were at stage 3. Recruitment
of the leukocytes to the inflamed site (the recipient ears) was measured by IVIS, revealing sig-
nificantly higher fluorescence in the ears of transgenic untreated mice, detectable from 3 hours
post injection (Fig 7 and Figure A in S3 File). Repeat of the assay in older mice of increased
phenotypic stage, revealed a correlation with the ear phenotype stage and the leukocyte
recruitment (Figures B and C and Table A in S3 File). These data extend the observations
above, showing that NAC treatment slows the progression of the inflamed phenotype (mea-
sured by multiple parameters), and this in turn reduces leukocyte recruitment to the site,
thereby tempering the escalation of the phenotype.
Discussion
EBV infection can lead to multiple post-viral inflammatory conditions as well as being a risk
factor for auto-immune disorders including MS and SLE. The viral-encoded protein LMP1 is
a potent inducer of inflammation [30], which may be at the root of many of these post-viral
syndromes. Non-steroidal anti-inflammatory drugs are extensively used in the treatment of
such conditions. Here, we have investigated the use of an anti-oxidant to boost the body’s
inherent redox regulatory mechanism, in an attempt to break the feed forward loop between
oxidative tissue damage and inflammation, which could persist after the virus departs.
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Fig 6. NAC treatment does not impact a set of proteins deregulated by LMP1. Ear tissue protein samples, taken from different mice were
analysed by western blotting for expression of the indicated proteins. (A) Samples from L2LMP1 transgene positive mice of increasing age and
stage are shown. (B) Samples were taken from NAC treated and control mice at 100 days old. LMP1 transgenic status (+ or -) and NAC
treatment (+ or -) are indicated above. Actin or GAPDH was used as a loading control. Protein size markers in kD are indicated to the left of each
panel.
https://doi.org/10.1371/journal.pone.0189167.g006
Table 1. Leukocyte recruitment. L2LMP1 transgenic mice were designated with numbers I to VII (as indi-
cated). Treatment with NAC (from 48 days old) or untreated is indicated (+,—respectively) and ear stage at
age 103 days. Mice I to VI were recipients for leukocytes (cells inj) collected from donor L2LMP1 stage 5 ears.
# Tg NAC Age stage Cells inj
I + + 103 2 106
II + + 103 2 106
III + + 103 2 106
IV + - 103 3 106
V + - 103 3 106
VI + - 103 3 106
VII + - 103 3 none
https://doi.org/10.1371/journal.pone.0189167.t001
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We have used the L2LMP1 transgenic mouse model, where the skin develops a pathology
of hyperplasia and increasing chronic inflammation, most severe where LMP1 is expressed to
the highest level (in the skin of the ears) [28, 30, 31]. The expression levels of a large number of
proteins are consequently affected, notably those involved in the control of cell proliferation
and inflammatory processes [39]. As the phenotype progresses in adult mice, there is an
increasing influx of immune cells and concomitant increase in the levels of multiple chemo-
kines and cytokines released by these cells, promulgating the chronic inflammatory state [30].
We have previously shown that IgG deposition in the dermis forms part of this process and
now show that it also involves the increased deposition of IgM, IgA, and IgE and activation of
complement. Genetic deletion of CD40, one of the many induced factors in the pathological
Fig 7. Leukocyte recruitment to the inflamed tissue correlates with phenotypic stage, which is ameliorated by NAC treatment. CPD
stained leukocytes collected from inflamed L2LMP1 transgenic stage 5 ears were injected into six L2LMP1 transgenic mice (aged 103 days
old), three of which had received NAC treated water (NAC) and three were not treated (UT). Mice were imaged at 3, 24 and 48 hours post
injection (hpi). Top: typical epifluorescent image taken at 3 and 24 hpi. Below: the average radiant efficiency of the ROI (taken around the ear)
is plotted (n = 6 for each, error bars show SEM). The average of each of the readings taken (6 repeats) for un-injected control mouse VII
(Table 1), is plotted as the base line. The difference between NAC and UT is significant at each time point (p<0.0001, 0.0018, 0.0002
respectively).
https://doi.org/10.1371/journal.pone.0189167.g007
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tissue, with accompanying loss of IgG, IgE and complement activation, reduces the character-
istic degenerative features (necrosis and ulceration) of stages 4 and 5 of the phenotype. By
comparison, in the complete absence of mature B and T-cells in a RAG1 null background, the
phenotype was limited to stage 2 [30]. These data allow a partial separation of the role of T and
B-cells in the pathology, suggesting that the B-cell factors contribute more to the tissue-
destructive aspects. This is consistent with what is observed in several chronic inflammatory
conditions which feature immunoglobulin deposition, such as rheumatoid arthritis, where
treatments to deplete B-cells (for example Rituximab, an antibody to CD20) are effective in
reducing joint damage and pain [43].
With the milieu of chemokines and cytokines involved in the inflammatory process, tar-
geting any one may have limited effect and/or unwanted side effects. We instead sought to
inhibit the feed forward loop between inflammation and oxidative stress and tissue damage,
using a readily available, non-toxic antioxidant. NAC provides L-cysteine (a semi-essential
amino acid) in the synthesis of the body’s natural major antioxidant, GSH, which may
become depleted during inflammation. We show that long term NAC treatment reduces the
leukocyte load in the inflamed tissue and thus the inflammatory pathology. This is evi-
denced by the visible phenotype and using a quantifiable, in vivo imaging assay for inflam-
mation. The reduction in inflammation achieved through NAC treatment has the knock on
effect of reducing further leukocyte recruitment to the tissue, thus damping the rate of phe-
notype progression.
As expected, NAC treatment did not have an impact on the expression levels of genes
deregulated by LMP1 in this model, such as TGFα, S100A9 and the chitinase like proteins
Chil3 and Chil4. However, any effect on signal transduction pathway components is more dif-
ficult to address. In a non-neoplastic tissue, the steady-state activation status of a pathway can
be difficult to dissect, as several feedback loops are in place to counter-balance constitutive
activation. For example, in TGFα overexpressing transgenic mice, with constitutive stimula-
tion of EGFR, the levels of EGFR become down-regulated even though the pathway is still
active [40]. This is also observed in the L2LMP1 transgenic mice where TGFα expression is
continuously induced by LMP1 action and EGFR becomes downregulated as a consequence of
persistent activation. Genetic deletion of TGFα transiently relieves the negative feedback to
reveal the underlying induction of EGFR and downstream pathways [31]. If NAC treatment
impacts the MAPK pathway in the inflamed tissue, it is not apparent, as EGFR down regula-
tion, mirrored by the down regulation of Erk activation in later phenotypic stages, is not
changed with NAC treatment. Similarly, NAC treatment of cultured cells has been shown to
inhibit NF-κB activation through suppressing the phosphorylation of IκB leading to its degra-
dation (an NF-κB inhibitor) [44]. With long term NAC treatment in vivo, we see no impact on
the levels and phosphorylation of IκBα in the inflamed tissue, but as described above, as the
steady-state levels reflect a balance of pathway activation and feedback regulation in the intact
tissue, the underlying processes may be obscured.
Conclusions
LMP1 is regarded as the primary oncogene of EBV in activating proliferative, cell survival and
inflammatory pathways. EBV-associated cancers with expression of LMP1, notably NPC and
HD, have a prominent leukocyte infiltrate. Increasing evidence suggests that a tumour leuko-
cyte infiltrate plays a cancer cell supportive role [45]. While the use of antioxidants in cancer
treatment and prevention is much debated, and the effects are likely to be cancer-type depen-
dant, the use of NAC in the treatment of inflammation-associated and EBV/LMP1-associated
cancers could be explored.
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In the L2LMP1 transgenic model, the pathology is continually triggered by LMP1 expres-
sion and it is therefore not expected that any treatment (that doesn’t target LMP1 directly)
would “cure” the phenotype. Nevertheless, NAC treatment slowed pathologic progression and
it could prove to be a valuable treatment option for ameliorating chronic inflammatory pathol-
ogies. Indeed, with post-viral diseases and conditions, NAC treatment might facilitate resolu-
tion of the inflammation.
We have described a model of chronic inflammation of the skin, primarily displayed in the
ears of the mouse. This tissue is not only readily accessible and visibly monitored, but permits
quantitation of the inflammation through in vivo imaging. We have characterised the prote-
ome through the progressive pathology [39], the cellular infiltrate, cytokine and chemokine
profiles [30] and here, optimised an in vivo imaging approach. Together, these provide a com-
prehensive platform to assess treatment options for chronic inflammation, whatever the
trigger.
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